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Sir,
Hidradenitis suppurativa (HS) is a chronic, recurring, 
debilitating inflammatory skin disease, which mainly 
affects the inverse areas of the body leading to scarring 
and disfigurement (1, 2).  
The European S1 guideline for the treatment of HS 
summarized all published treatments for HS (1). The 
quality of evidence for these treatments is generally 
low, as was recently demonstrated in a Cochrane Re-
view on interventions for HS, which identified only 12 
randomized controlled trials (RCTs) (3). Moreover, HS 
is a heterogeneous disease with distinct clinical pheno-
types that may require different treatment strategies, 
further complicating the therapeutic decision-making 
process (4). 
The European S1 guideline proposed a “Hurley se-
verity grade-relevant treatment algorithm” (1). More 
recently Gulliver et al. (5) proposed another treatment 
algorithm based on disease severity measured by Hurley 
grade or PGA. 
Hurley stage is a 3-stage classification of severity. 
Hurley stage I is characterized by abscess formation 
with out sinus tracts and scarring. In Hurley II, patients 
have single or multiple separated areas of recurrent ab-
scesses with sinus tracts and scarring, whereas in stage 
III the multiple interconnected sinus tracts and abscesses 
cover the whole affected anatomi-
cal area. This classification in its 
original form was created mainly 
for surgical purposes and does not 
take into account the inflammatory 
component. In addition, the exten-
sion of the disease, i.e. the number 
of anatomical areas involved, is not 
assessed. Accurate stratification 
of the wide variety of HS clinical 
phenotypes is therefore not pos-
sible with the original Hurley score. 
Furthermore, the recently in-
vented dynamic scoring system 
Hidradenitis Suppurativa Clinical 
Response (6) focuses mainly on 
the inflammatory component and 
is more or less comparable with a 
PASI 50 improvement in psoriasis 
and therefore is mainly suitable 
for the follow-up of systemic 
treatments. How ever, these scores do not calculate or 
include the extensiveness of the disease. The number of 
anatomical areas involved is important in designing a 
holistic treatment plan as this should take into account 
the estimated number of surgical interventions needed 
(Fig. S11).
Here, we (the Dutch HS expert group and as a part 
of the European Hidradenitis Suppurativa Foundation 
e.V.) propose a refinement of the current Hurley staging. 
Briefly, a 3 stepwise algorithm, including assessing 
the presence of sinus tracts, degree of inflammation and 
the extensiveness, enables the clinician to assess severity 
across the different phenotypes of HS and helps to guide 
treatment (Fig. 1).
In the first step of the algorithm the presence of sinus 
tracts is assessed, clearly separating Hurley I from Hurley 
II and III. In Hurley I the differentiation between fixed 
and migratory lesions is essential. Hurley 1C is consi-
dered as severe HS and is characterized by the presence 
of migratory lesions and corresponds with the recently 
proposed scarring folliculitis and frictional furuncle 
phenotype (4). Since migratory lesions point to a strong 
inflammatory component, the cornerstone of treatment 
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Fig. 1. Refinement of the Hurley classification: the 3-step algorithm. BSA: body surface area.
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is anti-inflammatory agents rather than surgery. The 
difference between mild (A) and moderate (B) Hurley 
I is essential as it determines the extent of a potential 
surgical intervention.
Hurley stage II is characterized by the presence of 
sinus tracts and no longer by the presence of scarring, 
since this does not change the choice of treatment. In 
Hurley stage II the presence of inflammation (step 2), 
the extensiveness (step 3), whether 2 or more anatomi-
cal regions are involved, define the grade of severity 
and the choice of treatment (Fig. S21). In Hurley II 
without active inflammation, surgery is the first-line 
therapy, whereas pre- or perioperative anti-inflammatory 
treatment should be considered when inflammation is 
present. 
Hurley III is redefined as ≥ 1% body surface area 
(BSA) of a body site with interconnected inflammatory 
sinus tracts. In the original Hurley score an entire area 
must have been affected. In our view this refinement 
of Hurley III is necessary as there are large differences 
in surface size between anatomical areas; for example 
buttock vs. armpit. 
In conclusion, our classification and the attached treat-
ment ladder provide an easy way for clinicians to make 
a holistic therapeutic plan. First, it recognizes patients 
within Hurley I and II to have severe disease. Secondly, 
the definition of Hurley III is redefined as ≥1% BSA 
of a body site, to equalize the size of anatomical areas, 
which allows the earlier diagnosis of severe Hurley III 
in larger anatomical areas. The modifications help the 
clinician to guide therapy, especially in the choice bet-
ween surgery and/or adjuvant anti-inflammatory drugs. 
Furthermore, the modifications provide the opportunity 
to prescribe anti-tumour necrosis factor (TNF) biologics 
for patients with Hurley stage 1C in whom surgery is not 
the appropriate option.
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